Anavex Life Sciences Corp (AVXL)

[TomP1]

I believe you are referring to this paragraph?

Other income (expenses)

The aggregate amount in the other income (expense) for the year ended September 30, 2016, amounted to $0.9 million as compared to $(5.0) million for the comparable year ended September 30, 2015.

22


The largest reason for the increase in other income was a result of an amount of $0.7 million in grant income received during the period. We received a grant in the amount of $0.57 million as part of a research and development incentive program offered by the Australian government, in connection with eligible expenditures on our Phase 2a clinical trial, which was conducted in Australia. In addition, we received a research grant from the Michael J. Fox Foundation (“MJFF”) to develop ANAVEX TM 2-73 for the treatment of Parkinson’s disease. The MJFF research grant is being received over a period of two years and is being recognized into income as the related expenditures are incurred. During the year ended September 30, 2016, we recognized $0.14 million of this grant on our statement of operations.

However, none of this is "new" money, to fund p2/3 Alzheimer.